Evidence map›Paper›PMID 39569034›Full record

ArticleIn silico pharmacology2024

QSAR, molecular docking, MD simulations, and ADMET screening identify potential

Emmanuel Sunday Omirin, Precious Oluwasanmi Aribisala, Ezekiel Abiola Olugbogi, Olawole Yakubu Adeniran, Sunday Adeola Emaleku, John Ayodeji Saliu, Oluwaseun Fapohunda, Abimbola Kikelomo Omirin, Mary Oyinlola Gbadamosi, Iheanyichukwu Wopara

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in In silico pharmacology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Emmanuel Sunday OmirinEureka Laboratory, Babcock University, Ilishan-Remo, Ogun State Nigeria.
Precious Oluwasanmi AribisalaEureka Laboratory, Babcock University, Ilishan-Remo, Ogun State Nigeria.
Ezekiel Abiola OlugbogiEureka Laboratory, Babcock University, Ilishan-Remo, Ogun State Nigeria.
Olawole Yakubu AdeniranDepartment of Biochemistry, Adekunle Ajasin University, Akungba Akoko, Ondo State Nigeria.
Sunday Adeola EmalekuDepartment of Biochemistry, Adekunle Ajasin University, Akungba Akoko, Ondo State Nigeria.
John Ayodeji SaliuDepartment of Biochemistry, Adekunle Ajasin University, Akungba Akoko, Ondo State Nigeria.
Oluwaseun FapohundaDepartment of Biochemistry, Adekunle Ajasin University, Akungba Akoko, Ondo State Nigeria.
Abimbola Kikelomo OmirinDepartment of Chemistry, Federal Polytechnic, Ado-Ekiti, Nigeria.
Mary Oyinlola GbadamosiDepartment of Biochemistry, Federal University of Technology, Akure, Nigeria.
Iheanyichukwu WoparaDepartment of Biochemistry, Rivers State University, Port Harcourt, Rivers State Nigeria.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Steroid 5α-reductase (5αR) converts testosterone into dihydrotestosterone (DHT), a potent androgen driving prostate cell proliferation via the androgen receptor (AR). Both 5αR and AR play crucial roles in androgen-mediated disorders, making them key therapeutic targets in drug development. Current treatments target these enzymes individually and often cause significant side effects, highlighting the need for safer alternatives. Through Supplementary Information: The online version contains supplementary material available at 10.1007/s40203-024-00280-7.

Indexed as

5AR and ARHeliotropium indicumIn silicoMachine learningMD SimulationPharmacokinetic

Identifiers

PMID39569034
PMCPMC11573971

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.